LivaNova PLC Announces Approval of Perceval
LONDON, 2016-01-11 15:00 CET (GLOBE NEWSWIRE) --
LivaNova PLC (NASDAQ:LIVN) (LSE:LIVN) (the “Company”) announced that, on January 8, 2016, the Company received approval from the United States Food and Drug Administration (“FDA”) for the Perceval Sutureless Heart Valve (“Perceval”). The approval is effective immediately, and the Company will begin commercial distribution of the device in the U.S. over the coming quarter.
Perceval is a surgical aortic valve with a unique self-anchoring frame that enables the surgeon to replace the diseased valve without suturing it into place. The valve’s functional component is made of bovine pericardium and is mounted on a super-elastic alloy frame. Clinical results in patients implanted with Perceval have shown a significant reduction in surgical procedural time for both isolated and complex aortic valve replacement with aortic cross-clamp times typically reduced by at least 50%.
“We are excited to bring this important product to the U.S. market, which will provide real value to patients and physicians,” said André-Michel Ballester, Chief Executive Officer. “The rapid acceptance of Perceval in Europe, an increasing number of positive publications on the product, and the solid preparation of our U.S. sales team, all provide a strong base for the achievement of our short and long term plans,” concluded Mr. Ballester.
Perceval is indicated for the replacement of diseased, damaged, or malfunctioning native or prosthetic aortic valves. The sale and distribution of the Perceval heart valve is limited to prescription use by specially-trained practitioners, and the Company has developed a nationwide training and proctoring program to help ensure the safety and effectiveness of the device.
LivaNova PLC, headquartered in London, UK, is a global medical technology company formed by the merger of Sorin S.p.A, a leader in the treatment of cardiovascular diseases, and Cyberonics Inc., a medical device company with core expertise in neuromodulation. LivaNova transforms medical innovation into meaningful solutions for the benefit of patients, healthcare professionals, and healthcare systems. The company employs approximately 4,500 employees worldwide. With a presence in more than 100 countries, LivaNova operates as three business units: Cardiac Rhythm Management, Cardiac Surgery, and Neuromodulation, with operating headquarters in Clamart (France), Mirandola (Italy) and Houston (U.S.A.), respectively.
LivaNova is listed on NASDAQ and listed on the Official List of the UK’s Financial Conduct Authority and traded on London Stock Exchange (LSE) under the ticker symbol “LIVN”.
For more information, please visitwww.livanova.com, or contact:
Chief Financial Officer
Investor Relations and Media:
Senior Vice President, Finance
Phone: +1 (281) 228-7262
Fax: +1 (281) 218-9332
Information om Nasdaq OMX
Følg pressemeddelelser fra Nasdaq OMX
Skrive dig op her og du vil løbende modtage pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Nasdaq OMX
Cisco16.2.2018 14:02 | pressemeddelelse
Cisco Offers Cloud-Based Endpoint Security Solutions for Managed Security Service Providers
SEMAFO Inc.16.2.2018 03:37 | pressemeddelelse
SEMAFO: Positive Mana PFS and Reserve Additions at Mana and Boungou
SEMAFO Inc.16.2.2018 01:39 | pressemeddelelse
SEMAFO Provides 2018 Outlook
Cornell University15.2.2018 14:54 | pressemeddelelse
Cornell receives $35M to support cassava development for smallholder farmers in sub-Saharan Africa
Komet Resources Inc.15.2.2018 14:51 | pressemeddelelse
Komet - Closing of the Second Tranche of a Private Placement
Cisco15.2.2018 00:03 | pressemeddelelse
Cisco Reports Second Quarter Earnings
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum